Key Takeaways
- • Benchmark maintained a Buy rating and $55.00 price target on Proto Labs (NYSE: PRLB) ahead of the company's fourth quarter 2025 earnings release, with the stock trading at $52.48 near its 52-week high of $56.60.
- • Benchmark analyst Robert Wasserman projects Q4 2025 revenues of $130.2 million (6.9% year-over-year growth) and non-GAAP EPS of $0.36, compared to consensus estimates of $129.0 million revenue (5.9% growth) and $0.35 EPS.
- • Proto Labs' manufacturing demand outlook remains a focal point, with analyst attention on cost controls, revenue growth momentum, tariff impacts, and manufacturing reshoring trends as key earnings drivers.
- • The consensus price target across three analysts stands at approximately $81.00 (ranging from $82–$91), suggesting modest upside from current levels, though InvestingPro data indicates the stock appears overvalued on a fair value basis.
- • Proto Labs holds a market cap of $1.24 billion with trailing twelve-month revenue of $518.38 million and maintains a stronger cash position relative to debt, with three analysts revising earnings upward for the upcoming period.
Summary
Benchmark maintained its Buy rating and $55.00 price target on Proto Labs (NYSE: PRLB) ahead of the company's fourth quarter 2025 earnings announcement, scheduled for Friday before market open with a conference call at 8:30 am Eastern time. The stock was trading at $52.48, near its 52-week high of $56.60, positioning the company within striking distance of analyst price targets despite mixed valuation signals from market data providers.
Benchmark analyst Robert Wasserman's estimates for Q4 2025 project revenues of $130.2 million, representing 6.9% year-over-year growth, with non-GAAP EPS of $0.36. This contrasts with broader consensus expectations of $129.0 million in revenue (5.9% growth) and $0.35 EPS, while company guidance indicates a wider range of $125–$133 million in revenues and $0.30–$0.38 in non-GAAP EPS. The variance between analyst estimates and guidance suggests material uncertainty regarding fourth quarter performance and the sustainability of manufacturing demand tailwinds.
Key focal points for the earnings report include Proto Labs' cost control execution, revenue growth momentum from Q3, revenue per customer contact metrics, and the impact of tariffs and manufacturing reshoring on operational performance. These factors underscore the market's interest in whether the company can sustain growth in an environment shaped by supply chain dynamics and tariff policies. The consensus price target across three analysts stands at approximately $81.00 (with estimates ranging from $82–$91), suggesting modest upside potential, though InvestingPro assessments indicate the stock may be trading at elevated valuations relative to fundamental metrics.
Proto Labs maintains a $1.24 billion market capitalization with trailing twelve-month revenue of $518.38 million. The company's balance sheet position—with cash exceeding debt—provides financial flexibility, while three analysts have recently revised earnings estimates upward, indicating some confidence in near-term performance despite broader market valuation concerns.
Benchmark analyst Robert Wasserman's estimates for Q4 2025 project revenues of $130.2 million, representing 6.9% year-over-year growth, with non-GAAP EPS of $0.36. This contrasts with broader consensus expectations of $129.0 million in revenue (5.9% growth) and $0.35 EPS, while company guidance indicates a wider range of $125–$133 million in revenues and $0.30–$0.38 in non-GAAP EPS. The variance between analyst estimates and guidance suggests material uncertainty regarding fourth quarter performance and the sustainability of manufacturing demand tailwinds.
Key focal points for the earnings report include Proto Labs' cost control execution, revenue growth momentum from Q3, revenue per customer contact metrics, and the impact of tariffs and manufacturing reshoring on operational performance. These factors underscore the market's interest in whether the company can sustain growth in an environment shaped by supply chain dynamics and tariff policies. The consensus price target across three analysts stands at approximately $81.00 (with estimates ranging from $82–$91), suggesting modest upside potential, though InvestingPro assessments indicate the stock may be trading at elevated valuations relative to fundamental metrics.
Proto Labs maintains a $1.24 billion market capitalization with trailing twelve-month revenue of $518.38 million. The company's balance sheet position—with cash exceeding debt—provides financial flexibility, while three analysts have recently revised earnings estimates upward, indicating some confidence in near-term performance despite broader market valuation concerns.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.